MITOCHONDRIAL OXODICARBOXYLATE CARRIER DEFICIENCY: METABOLIC MODELLING IDENTIFIES DISEASE MECHANISM
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
MetadataShow full item record
Boczonadi, V., King, M., Bansagi, B., Roos, A., Eyassu, F., Borchers, C., Lane, M., et al. (2017). MITOCHONDRIAL OXODICARBOXYLATE CARRIER DEFICIENCY: METABOLIC MODELLING IDENTIFIES DISEASE MECHANISM. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 22 (3), 245-245. https://doi.org/10.17863/CAM.26489
Members of the mitochondrial carrier family (SLC25) transport nucleotides, keto acids, amino acids, fatty acids, co-factors and inorganic ions across the mitochondrial inner membrane. Several inherited diseases with very variable clinical presentations are associated with dysfunctional mitochondrial carriers. We report a patient with childhood-onset spinal muscular atrophy and mitochondrial myopathy caused by a homozygous mutation in SLC25A21, encoding the mitochondrial oxodicarboxylate carrier (ODC). The mutation renders the carrier dysfunctional and, consequently, 2-oxoadipate cannot be imported into the mitochondrial matrix. Computer modelling of the metabolic defect caused by the mutation predicted that the impaired transport leads to accumulation of 2-oxoadipate, pipecolic acid and the known neurotoxin quinolinic acid, which were precisely confirmed by targeted metabolomics in serum and urine. Exposure of 2-oxoadipate and quinolinic acid reduced the level of mitochondrial complexes in SH-SY5Y cells in-vitro suggesting a possible pathomechanism. Here we demonstrate that 2-oxoadipate and quinolinic acid are toxic for spinal motor neurons and their increased levels may contribute to neuropathy.
This record's DOI: https://doi.org/10.17863/CAM.26489
This record's URL: https://www.repository.cam.ac.uk/handle/1810/279109